# US 2026/0097108 A1 · Polynucleotides and lentiviral vectors expressing non-structural antigens of a flavivirus selected from the group of denv, zikv and yfv, inducing protective cd8+ t-cell immunity in a host

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0097108 A1
- Document ID: US20260097108A1
- Status: Published application
- Kind: A1
- Application number: 19/120,869
- Filed: 2023-10-20
- Published: 2026-04-09
- Earliest claimed: 2022-10-21
- Applicants: Institut Pasteur; Theravectys
- Inventors: Pierre CHARNEAU; Kirill NEMIROV; Pierre AUTHIE; Philippe SOUQUE; Amandine NOIRAT; Fanny MONCOQ
- Web page: https://patentgrep.com/patent/US20260097108A1

## CPC

- A61K 39/12: Viral antigens
- A61P 31/12: Antivirals
- A61K 39/0012: {Lipids; Lipoproteins}
- A61P 31/14: for RNA viruses
- C07K 14/1825: {Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue}
- C07K 14/70539: {MHC-molecules, e.g. HLA-molecules}
- C12N 5/0602: {Vertebrate cells}
- C12N 7/04: Inactivation or attenuation; Producing viral sub-units
- C12N 15/625: {containing a sequence coding for a signal sequence}
- C12N 15/86: Viral vectors
- A61K 2039/525: {Virus}
- A61K 2039/5256: {expressing foreign proteins}
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/70: {Multivalent vaccine}
- C07K 2319/00: Fusion polypeptide
- C12N 2740/00042: virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- C12N 2740/15041: Use of virus, viral particle or viral elements as a vector
- C12N 2740/15043: viral genome or elements thereof as genetic vector
- C12N 2770/24134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The invention relates to recombinant polynucleotides encoding at least a recombinant polynucleotide expressing at least a first fusion polypeptide that comprises MHC class I T-cell epitopes suitable to elicit a T cell immune response in a host in need thereof, wherein the MHC class I T-cell epitopes originate from a plurality of antigens wherein the antigens comprise at least non-structural antigens and are from at least one flavivirus selected from the group of 10 Dengue virus (DENV), ZIKA virus (ZIKV) and Yellow Fever virus (YFV). The invention also relates to the polypeptides comprising polyepitopes of said antigens encoded by the recombinant polynucleotides.

## Claims

### Claim 1

A recombinant polynucleotide comprising at least one polynucleotide encoding a fusion polypeptide which comprises MHC class I T-cell epitopes suitable to elicit a T cell response, wherein the MHC class I T-cell epitopes originate from a plurality of non-structural or structural antigens wherein the antigens are from at least one flavivirus selected from the group of Dengue virus (DENV), ZIKA virus (ZIKV) and Yellow Fever virus (YFV) and wherein the MHC class I T-cell epitopes are assembled together through junction regions that are devoid of non-specific neoepitopes.

### Claim 2 (depends on 1)

A recombinant polynucleotide according to claim 1, comprising a first polynucleotide encoding a first fusion polypeptide which comprises MHC class I T-cell epitopes originating from more than one non-structural DENV proteins and forming an assembled DENV-based consensus antigen of DENV-1, DENV-2, DENV-3 and DENV-4 strains.

### Claim 3 (depends on 1)

The recombinant polynucleotide according to claim 1 wherein the MHC class I T-cell epitopes originate from at least 2 antigens of DENV selected from the group of the NS3, NS4A, NS4B and NS5 antigens.

### Claim 4 (depends on 1)

The recombinant polynucleotide according to claim 1, wherein the junction regions include hydrophobic amino acid linkers and are devoid of sequences encoding non-specific immunodominant epitopes.

### Claim 5 (depends on 1)

The recombinant polynucleotide according to claim 1 wherein the assembled polynucleotide comprises the polynucleotides encoding the MHC class I T-cell epitopes of SEQ ID No. 2, SEQ ID No. 4, SEQ ID No. 6, SEQ ID No. 8, SEQ ID No. 10, SEQ ID No. 12, SEQ ID No. 14, SEQ ID No. 16, SEQ ID No. 18, SEQ ID No. 20, SEQ ID No. 22, SEQ ID No. 24, SEQ ID No. 26 and SEQ ID No. 28 or a variant thereof which is devoid of SEQ ID No. 2.

### Claim 6 (depends on 1)

The recombinant polynucleotide according to claim 1 which is selected from:
a. a recombinant polynucleotide which comprises a polynucleotides encoding the MHC class I T-cell epitopes of the following sequences, arranged from 5′ to 3′ in the recombinant polynucleotide in accordance with the following order: SEQ ID No. 2, SEQ ID No. 4, SEQ ID No. 6, SEQ ID No. 8, SEQ ID No. 10, SEQ ID No. 12, SEQ ID No. 14, SEQ ID No. 16, SEQ ID No. 18, SEQ ID No. 20, SEQ ID No. 22, SEQ ID No. 24, SEQ ID No. 26 and SEQ ID No. 28 and wherein the junction regions between said polynucleotides encoding the MHC class I T-cell epitopes are devoid of sequences encoding non-specific immunodominant epitopes or,
b. the recombinant polynucleotide which comprises the polynucleotides encoding the MHC class I T-cell epitopes of the following sequences, arranged from 5′ to 3′ in the recombinant polynucleotide in accordance with the following order: SEQ ID No. 4, SEQ ID No. 6, SEQ ID No. 8, SEQ ID No. 10, SEQ ID No. 12, SEQ ID No. 14, SEQ ID No. 16, SEQ ID No. 18, SEQ ID No. 20, SEQ ID No. 22, SEQ ID No. 24, SEQ ID No. 26, SEQ ID No. 28, SEQ ID No. 32, SEQ ID No. 34 and SEQ ID No. 36 and wherein the junction regions between said polynucleotides encoding the MHC class I T-cell epitopes are devoid of sequences encoding non-specific immunodominant epitopes, in particular the recombinant polynucleotide wherein an amino acid linker sequence is inserted as a junction region between all consecutive above sequences except between SEQ ID No. 8 and SEQ ID No. 10, between SEQ ID No. 16 and SEQ ID No. 18, between SEQ ID No. 18 and SEQ ID No. 20 and between SEQ ID No. 34 and SEQ ID No. 36

### Claim 7 (depends on 1)

The recombinant polynucleotide according to claim 1, wherein the MHC class I T-cell epitopes originate from at least 2 antigens of ZIKV selected from the group of the NS4B and NS5 antigens and further MHC class I T-cell epitopes originate from at least 2 antigens of ZIKV selected from the group of the C and PrM antigens, wherein the MHC class I T-cell epitopes are assembled together through junction regions that are devoid of non-specific neoepitopes.

### Claim 8 (depends on 1)

The recombinant polynucleotide according to claim 1, wherein the polynucleotides encoding the MHC class I T-cell epitopes are arranged from 5′ to 3′ in the recombinant polynucleotide in accordance with the following order: SEQ ID No. 40, SEQ ID No. 42, SEQ ID No. 44, SEQ ID No. 46, SEQ ID No. 48, SEQ ID No. 50 and SEQ ID No. 52 and wherein the junction regions between said polynucleotides encoding the MHC class I T-cell epitopes are devoid of sequences encoding non-specific immunodominant epitopes, in particular the recombinant polynucleotide wherein an amino acid linker sequence is inserted as a junction region between all consecutive above sequences, except between SEQ ID No. 44 and SEQ ID No. 46 and between SEQ ID No. 50 and SEQ ID No. 52.

### Claim 9 (depends on 1)

The recombinant polynucleotide according to claim 1, wherein the MHC class I T-cell epitopes originate from at least 1 antigen of YFV selected from the group of the NS-1, NS-2A, NS2B, NS-3, NS-4 and NS4B and NS5 antigens and further MHC class I T-cell epitopes originate from at least 2 antigens of YFV selected from the group of C, M and E antigens, wherein the MHC class I T-cell epitopes are assembled together through junction regions that are devoid of non-specific neoepitopes.

### Claim 10 (depends on 1)

The recombinant polynucleotide according to claim 1, which is selected from:
a. a polynucleotide which comprises polynucleotides encoding the MHC class I T-cell epitopes arranged from 5′ to 3′ in the recombinant polynucleotide in accordance with the following order: SEQ ID No. 58, SEQ ID No. 60, SEQ ID No. 62, SEQ ID No. 64, SEQ ID No. 66, SEQ ID No. 68, SEQ ID No. 70, SEQ ID No. 72, SEQ ID No. 74, SEQ ID No. 76, SEQ ID No. 78, SEQ ID No. 80, SEQ ID No. 82, SEQ ID No. 84, SEQ ID No 86, SEQ ID No. 88, SEQ ID No. 90, SEQ ID No. 92, SEQ ID No. 94, SEQ ID No. 96, SEQ ID No. 98, SEQ ID No. 100, SEQ ID No. 102 and SEQ ID No. 104 and wherein the junction regions between said polynucleotides encoding the MHC class I T-cell epitopes are devoid of sequences encoding non-specific immunodominant epitopes, in particular the recombinant polynucleotide wherein an amino acid linker sequence is inserted as a junction region between all consecutive above sequences except between SEQ ID No. 60 and SEQ ID No. 62, between SEQ ID No. 66 and SEQ ID No. 68, between SEQ ID No. 74 and SEQ ID No. 76, between SEQ ID No. 78 and SEQ ID No. 80 and SEQ ID No. 82 and between SEQ ID No. 94 and SEQ ID No. 96, or
b. a polynucleotide which comprises polynucleotides encoding the MHC class I T-cell epitopes arranged from 5′ to 3′ in the recombinant polynucleotide in accordance with the following order: SEQ ID No. 108, SEQ ID No. 110, SEQ ID No. 112, SEQ ID No. 114, SEQ ID No. 116, SEQ ID No. 118, SEQ ID No. 120, SEQ ID No. 122, SEQ ID No. 124, SEQ ID No. 126, SEQ ID No. 128, SEQ ID No. 130, SEQ ID No. 132, SEQ ID No. 134, SEQ ID No. 136, SEQ ID No. 138 and SEQ ID No. 140 and wherein the junction regions between said polynucleotides encoding the MHC class I T-cell epitopes are devoid of sequences encoding non-specific immunodominant epitopes.

### Claim 11 (depends on 1)

The recombinant polynucleotide according to claim 1, which further contains a sequence encoding a signal peptide at its 5′-end.

### Claim 12 (depends on 1)

The recombinant polynucleotide according to claim 1, whose sequence consists of SEQ ID No. 29 or SEQ ID No. 37.

### Claim 13 (depends on 1)

The recombinant polynucleotide according to claim 1 wherein the sequence of the polynucleotide is modified with respect to the sequence of SEQ ID No. 29 or SEQ ID No. 37, wherein the modification consists of a point mutation, substitution or deletion of nucleotides, and the modified sequence encodes a fusion polypeptide that has at least 90% sequence identity with the sequence of the original fusion polypeptide.

### Claim 14 (depends on 1)

The recombinant polynucleotide according to claim 1, which comprises (i) a first polynucleotide encoding a first fusion polypeptide comprising MHC class I T-cell epitopes originating from structural and from non-structural DENV proteins and forming an assembled DENV-based antigen and (ii) a second polynucleotide encoding a second fusion polypeptide comprising MHC class I T-cell epitopes originating from structural and from non-structural ZIKV proteins and forming an assembled ZIKV-based antigen and/or (iii) a third polynucleotide encoding a second fusion polypeptide comprising MHC class I T-cell epitopes originating from structural and/or from non-structural YFV proteins and forming an assembled YFV-based antigen, wherein the first and, when present, the second and third polynucleotides are operably linked in an expression cassette and are separated by a sequence encoding a self-cleavage peptide optionally associated with a spacer sequence.

### Claim 15

A recombinant polyepitopic polypeptide whose amino acid sequence consists of SEQ ID No. 30, SEQ ID No. 38, SEQ ID No. 54, SEQ ID No. 56, SEQ ID No. 106, SEQ ID No. 142, or a variant thereof obtained by deletion or by point mutation of one or more amino acid residues and wherein the variant sequence has at least 90% sequence identity.

### Claim 16 (depends on 1)

A recombinant lentiviral vector genome comprising the recombinant polynucleotide according to claim 1.

### Claim 17 (depends on 16)

The recombinant lentiviral vector genome according to claim 16, wherein said genome is the insert obtained from a pFLAP vector plasmid selected from the group of pFlap-beta2m-DENV-Ag1-WPREm of SEQ ID No. 151, pFlap-beta2m-DENV-Ag2-WPREm of SEQ ID No. 152, pFlap-beta2m-ZIKV-Ag-WPREm of SEQ ID No. 153, pFlap-beta2m-ZIKV-NS1-WPREm of SEQ ID No. 154, pFlap-beta2m-YFV-Ag1-WPREm of SEQ ID No. 155, pFlap-beta2m-YFV-Ag2-WPREm of SEQ ID No. 156, pFlap-beta2m-DENV-Ag2_ZIKV-Ag-WPREm_(Flavi-2) of SEQ ID No. 157, pFlap-beta2m-ZIKV-Ag_DENV-Ag2-WPREm_(Flavi-3) of SEQ ID No. 158, pFlap-beta2m-DENV-Ag2_ZIKV-NS1-WPREm_(Flavi-4) of SEQ ID No. 159, and pFlap-beta2m-ZIKV-NS1-DENV-Ag2-WPREm_(Flavi-5) of SEQ ID No. 160.

### Claim 18 (depends on 1)

A recombinant lentiviral vector particle which comprises the recombinant lentiviral vector genome according to claim 1.

### Claim 19 (depends on 18)

The recombinant lentiviral vector particle according to claim 18, wherein said recombinant lentiviral vector particle is a recombinant replication-incompetent pseudotyped lentiviral vector particle.

### Claim 20 (depends on 1)

A mammalian host cell transfected with the recombinant polynucleotide according to claim 1.

### Claim 21 (depends on 1)

A composition suitable for administration to a human host, comprising the recombinant polynucleotide according to claim 1 together with one or more pharmaceutically acceptable excipient(s) suitable for administration to the human host and optionally an adjuvant.

### Claim 22 (depends on 21)

A method for the treatment of a patient with a flavivirus infection selected from the group of Dengue virus (DENV), ZIKA virus (ZIKV) and Yellow Fever virus (YFV) comprising the administration of an effective amount of the composition of claim 21 to the patient.

### Claim 23 (depends on 22)

The method of claim 22, wherein the DENV is and DENV-4.

### Claim 24 (depends on 22)

A The method of claim 22, wherein the composition is comprised in a multivalent vaccine.

### Claim 25 (depends on 22)

The method of claim 22, wherein the administration comprises a prime-boost administration regimen of the composition.
